share_log

BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by BMO Capital Markets

BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by BMO Capital Markets

BioMarin Pharmical(纳斯达克股票代码:BMRN)现已由 BMO 资本市场覆盖
Financial News Live ·  2023/02/03 02:23

BMO Capital Markets assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note published on Monday morning, The Fly reports. The brokerage issued a market perform rating and a $107.00 price target on the biotechnology company's stock.

据The Fly报道,蒙特利尔银行资本市场在周一上午发布的一份研究报告中假设了BioMarin制药公司(BMRN-GET Rating)的股票。该经纪公司对这家生物技术公司的股票发布了市场表现评级和107.00美元的目标价。

Several other equities analysts have also issued reports on the company. Evercore ISI raised their price objective on BioMarin Pharmaceutical to $130.00 in a report on Friday, December 2nd. Wedbush increased their target price on shares of BioMarin Pharmaceutical from $74.00 to $83.00 and gave the stock a neutral rating in a research note on Wednesday, January 11th. Morgan Stanley increased their target price on shares of BioMarin Pharmaceutical from $113.00 to $132.00 and gave the stock an overweight rating in a research note on Tuesday, January 24th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a market perform rating to an outperform rating and increased their target price for the stock from $92.00 to $110.00 in a research note on Monday, October 31st. Finally, Bank of America increased their target price on shares of BioMarin Pharmaceutical to $200.00 in a research note on Wednesday, January 4th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $119.39.

其他几位股票分析师也发布了关于该公司的报告。在12月2日星期五的一份报告中,Evercore ISI将他们对BioMarin制药公司的目标价上调至130.00美元。韦德布什将BioMarin制药公司股票的目标价从74.00美元上调至83.00美元,并在1月11日星期三的一份研究报告中给予该股中性评级。摩根士丹利在1月24日(周二)的一份研究报告中将他们对BioMarin Pharmtics的目标价从113.00美元上调至132.00美元,并给予该股加码评级。奥本海默在10月31日(星期一)的一份研究报告中将BioMarin Pharmtics的股票评级从市场表现上调至表现优于大盘,并将该股的目标价从92美元上调至110.00美元。最后,美国银行在1月4日星期三的一份研究报告中将BioMarin制药公司的股票目标价上调至200.00美元。4名股票研究分析师对该股的评级为持有,12名分析师对该股的评级为买入。根据MarketBeat.com的数据,该公司的平均评级为中等买入,共识目标价为119.39美元。

Get
到达
BioMarin Pharmaceutical
BioMarin制药公司
alerts:
警报:

BioMarin Pharmaceutical Stock Performance

BioMarin制药类股表现

Shares of BMRN stock opened at $112.84 on Monday. The stock's 50-day moving average is $107.14 and its two-hundred day moving average is $95.05. The firm has a market cap of $20.93 billion, a price-to-earnings ratio of 274.33 and a beta of 0.39. BioMarin Pharmaceutical has a 1 year low of $70.73 and a 1 year high of $117.77. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.54 and a current ratio of 5.15.

周一,宝马的股票开盘报112.84美元。该股的50日移动均线切入位为107.14美元,200日移动均线切入位为95.05美元。该公司的市值为20.3亿美元,市盈率为274.33倍,贝塔系数为0.39%。BioMarin制药公司的一年低点为70.73美元,一年高位为117.77美元。该公司的负债权益比率为0.24,速动比率为3.54,流动比率为5.15。

Insider Activity

内幕活动

In other news, EVP Jeffrey Robert Ajer sold 49,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, January 25th. The shares were sold at an average price of $115.70, for a total transaction of $5,669,300.00. Following the completion of the sale, the executive vice president now directly owns 41,088 shares in the company, valued at approximately $4,753,881.60. The transaction was disclosed in a legal filing with the SEC, which is available through
在其他新闻方面,执行副总裁杰弗里·罗伯特·阿杰在1月25日星期三的一笔交易中出售了4.9万股BioMarin制药公司的股票。这些股票以115.70美元的平均价格出售,总成交金额为5669,300.00美元。出售完成后,执行副总裁总裁现在直接持有公司41,088股,价值约4,753,881.60美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过
. In other news, CEO Jean Jacques Bienaime sold 1,500 shares of the firm's stock in a transaction that occurred on Friday, December 2nd. The shares were sold at an average price of $103.98, for a total transaction of $155,970.00. Following the completion of the transaction, the chief executive officer now directly owns 321,424 shares of the company's stock, valued at approximately $33,421,667.52. The sale was disclosed in a filing with the SEC, which is available at
。在其他新闻方面,首席执行官Jean Jacques Bienaime在12月2日星期五的一笔交易中出售了1,500股公司股票。这些股票以103.98美元的平均价格出售,总成交金额为155,970.00美元。交易完成后,首席执行官现在直接拥有321,424股公司股票,价值约33,421,667.52美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在
. Also, EVP Jeffrey Robert Ajer sold 49,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $115.70, for a total transaction of $5,669,300.00. Following the transaction, the executive vice president now directly owns 41,088 shares of the company's stock, valued at $4,753,881.60. The disclosure for this sale can be found
。此外,执行副总裁杰弗里·罗伯特·阿杰在1月25日星期三的一次交易中出售了49,000股公司股票。股票以115.70美元的平均价格出售,总成交金额为5669,300.00美元。交易完成后,执行副总裁总裁现在直接持有该公司41,088股股票,价值4753,881.60美元。关于这次销售的披露可以找到
. In the last three months, insiders sold 88,880 shares of company stock worth $9,987,833. Company insiders own 1.75% of the company's stock.
。在过去的三个月里,内部人士卖出了88,880股公司股票,价值9,987,833美元。公司内部人士持有该公司1.75%的股份。

Institutional Inflows and Outflows

机构资金流入和流出

Hedge funds have recently modified their holdings of the business. Altshuler Shaham Ltd purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $25,000. Quadrant Capital Group LLC grew its stake in BioMarin Pharmaceutical by 188.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 232 shares during the period. Acadian Asset Management LLC grew its stake in BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 344 shares during the period. Capital Wealth Alliance LLC purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $34,000. Finally, Baystate Wealth Management LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $41,000. 96.26% of the stock is owned by hedge funds and other institutional investors.

对冲基金最近调整了对该业务的持股。Altshuler Shaham Ltd在第三季度购买了BioMarin制药公司的新头寸,价值约25,000美元。跨骏资本集团第二季度在BioMarin制药公司的持股增加了188.6%。跨骏资本集团在此期间额外收购了232股,现在拥有355股这家生物技术公司的股票,价值2.9万美元。Acadian资产管理有限责任公司在第一季度增持了395.4%的BioMarin制药股份。Acadian Asset Management LLC在此期间额外收购了344股,现在拥有431股这家生物技术公司的股票,价值3.2万美元。资本财富联盟有限责任公司在第二季度购买了BioMarin制药公司的新股份,价值约3.4万美元。最后,BayState Wealth Management LLC在第四季度购买了BioMarin制药公司的新股份,价值约4.1万美元。96.26%的股票由对冲基金和其他机构投资者持有。

BioMarin Pharmaceutical Company Profile

BioMarin制药公司简介

(Get Rating)

(获取评级)

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

BioMarin制药公司致力于为患有严重和危及生命的罕见疾病和医疗条件的人开发治疗方法并将其商业化。它的流水线产品包括Valoctocogene roxparvovec、vosoritie和BMN 307。该公司由约翰·C·克洛克、克里斯托弗·M。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
  • Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
  • Mullen Automotive Stock Gains Momentum On Positive News
  • Harley-Davidson Inc. Stock, Is It Time To Buy?
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • 免费获取StockNews.com关于BioMarin制药公司(BMRN)的研究报告
  • 凯西·伍兹的方舟创新ETF将在2023年反弹?
  • 马伦汽车公司股票因利好消息而上涨
  • 哈雷-戴维森公司的股票,是时候买入了吗?
  • Meta平台的底部已经到了,波动性还没有结束
  • 阿拉斯加航空公司近期收益分析

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

获得《BioMarin药学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioMarin制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发